|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 31/08/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 31/12/2022 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 03/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 25/08/2016 |
Günter von Au
CHM | Chairman | 75 | 26/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +3.49% | +10.04% | +58.68% | +119.56% | 1,106B | ||
| +2.19% | +4.32% | +33.88% | +69.52% | 612B | ||
| +2.26% | +5.37% | +24.57% | +97.69% | 500B | ||
| +2.58% | +8.31% | +37.43% | +63.51% | 367B | ||
| +3.25% | +4.45% | +71.80% | +44.44% | 354B | ||
| +1.85% | +5.45% | +21.38% | +49.26% | 286B | ||
| +1.76% | +4.92% | +0.48% | +20.31% | 256B | ||
| +3.29% | +6.32% | +44.71% | +57.43% | 230B | ||
| +2.25% | +5.81% | +27.13% | +101.17% | 190B | ||
| Average | +2.40% | +1.72% | +35.56% | +69.21% | 390.59B | |
| Weighted average by Cap. | +2.89% | +2.29% | +40.70% | +80.58% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















